Optimal induction and post-remission therapy for acute myeloid leukemia

The approach to treatment of acute myeloid leukemia is substantially influenced by the age of the patient. Younger patients who are arbitrarily defined as those being <60 years, although comprising the minority of all patients with the disease, will always receive an intensive approach, whereas in older patients, an initial decision as to whether an intensive approach is appropriate or not has to be made. Standard chemotherapy for many years has been '3+7', followed by consolidation with high-dose Ara-C at a daily dose level of 3 g/m(2). It remains unclear as to what number of total treatment courses is optimal. Alternatives to this standard of care will be considered.